0.8025
price down icon5.60%   -0.0476
after-market Handel nachbörslich: .79 -0.0125 -1.56%
loading
Schlusskurs vom Vortag:
$0.8501
Offen:
$0.826
24-Stunden-Volumen:
508.82K
Relative Volume:
1.13
Marktkapitalisierung:
$53.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-0.9286
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
-56.62%
1M Leistung:
-44.66%
6M Leistung:
-67.38%
1J Leistung:
-43.88%
1-Tages-Spanne:
Value
$0.80
$0.85
1-Wochen-Bereich:
Value
$0.7113
$1.90
52-Wochen-Spanne:
Value
$0.7113
$2.815

Inflarx N V Stock (IFRX) Company Profile

Name
Firmenname
Inflarx N V
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
74
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-21
Name
Neueste SEC-Einreichungen
Name
IFRX's Discussions on Twitter

Vergleichen Sie IFRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IFRX
Inflarx N V
0.8025 125.33M 0 -46.12M -41.02M -0.8642
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Inflarx N V Stock (IFRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2023-04-05 Hochstufung Guggenheim Neutral → Buy
2022-02-28 Herabstufung Guggenheim Buy → Neutral
2021-10-28 Hochstufung Raymond James Outperform → Strong Buy
2021-03-11 Hochstufung Guggenheim Neutral → Buy
2020-11-06 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-10-08 Eingeleitet H.C. Wainwright Buy
2020-06-17 Eingeleitet BTIG Research Buy
2020-04-30 Hochstufung Raymond James Mkt Perform → Outperform
2019-06-05 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-06-05 Herabstufung Guggenheim Buy → Neutral
2019-06-05 Herabstufung JP Morgan Overweight → Underweight
2019-06-05 Herabstufung Robert W. Baird Outperform → Neutral
2019-06-05 Herabstufung SunTrust Buy → Hold
2019-01-29 Eingeleitet Robert W. Baird Outperform
2018-12-10 Eingeleitet Credit Suisse Outperform
2018-07-13 Eingeleitet BMO Capital Markets Outperform
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-28 Eingeleitet SunTrust Buy
2018-02-08 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Inflarx N V Aktie (IFRX) Neueste Nachrichten

pulisher
May 30, 2025

InflaRx (NASDAQ:IFRX) Price Target Cut to $3.00 by Analysts at Oppenheimer - Defense World

May 30, 2025
pulisher
May 30, 2025

InflaRx stock rating cut, price target slashed to $2 by Raymond James - Investing.com Nigeria

May 30, 2025
pulisher
May 29, 2025

InflaRx (IFRX) Maintains Outperform Rating, Price Target Adjusted | IFRX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

IFRX Price Target Cut as Phase 3 Trial Halts | IFRX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Guggenheim maintains $10 target on Inflarx despite study halt - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Sto - GuruFocus

May 29, 2025
pulisher
May 29, 2025

InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

InflaRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks

May 29, 2025
pulisher
May 28, 2025

Top Midday Decliners - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Crude Oil Gains 2%; Macy's Lowers Earnings Forecast - Benzinga

May 28, 2025
pulisher
May 28, 2025

Guggenheim maintains $10 target on Inflarx despite study halt By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga

May 28, 2025
pulisher
May 28, 2025

PG rating: Inflarx review declares phase III bomb - BioWorld MedTech

May 28, 2025
pulisher
May 28, 2025

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial - insights.citeline.com

May 28, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 28, 2025

InflaRx (IFRX) Halts Key Drug Trials, Refocuses Strategy - GuruFocus

May 28, 2025
pulisher
May 28, 2025

InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum - TipRanks

May 28, 2025
pulisher
May 28, 2025

InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus - GuruFocus

May 28, 2025
pulisher
May 28, 2025

InflaRx to discontinue vilobelimab indication following IDMC recommendation - TipRanks

May 28, 2025
pulisher
May 28, 2025

InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus | IFRX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire Inc.

May 28, 2025
pulisher
May 27, 2025

InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp - Defense World

May 27, 2025
pulisher
May 22, 2025

InflaRx to Participate in Upcoming Investor Conferences - The Manila Times

May 22, 2025
pulisher
May 22, 2025

InflaRx Sets Ambitious Investor Conference Tour: Jefferies, Oppenheimer, and Leerink Partners Ahead - Stock Titan

May 22, 2025
pulisher
May 20, 2025

Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX) - Defense World

May 20, 2025
pulisher
May 16, 2025

Schonfeld Strategic Advisors LLC Sells 7,756 Shares of InflaRx (NASDAQ:IFRX) - Defense World

May 16, 2025
pulisher
May 14, 2025

Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com

May 14, 2025
pulisher
May 13, 2025

Raymond James maintains Strong Buy on Inflarx stock, $13 target By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Raymond James maintains Strong Buy on Inflarx stock, $13 target - Investing.com

May 13, 2025
pulisher
May 12, 2025

FY2025 EPS Estimates for InflaRx Raised by Cantor Fitzgerald - Defense World

May 12, 2025
pulisher
May 12, 2025

Q2 Earnings Forecast for InflaRx Issued By Leerink Partnrs - Defense World

May 12, 2025
pulisher
May 11, 2025

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024) - Yahoo Finance

May 11, 2025
pulisher
May 08, 2025

Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation - Nasdaq

May 08, 2025
pulisher
May 08, 2025

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga

May 08, 2025
pulisher
May 08, 2025

InflaRx N.V. Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

InflaRx reports Q1 EPS (EUR 0.13) vs (EUR 0.17) last year - TipRanks

May 07, 2025
pulisher
May 07, 2025

InflaRx Reports Q1 2025 Financial Results with Reduced Losses - TipRanks

May 07, 2025
pulisher
May 07, 2025

InflaRx (IFRX) Awaits Key Milestones in Drug Development | IFRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

InflaRx N.V. Announces Progress in Toxicology Studies for INF904 and Upcoming Phase 3 Interim Analysis of Vilobelimab - Nasdaq

May 07, 2025
pulisher
May 07, 2025

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 07, 2025
pulisher
May 05, 2025

InflaRx NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World

May 05, 2025
pulisher
May 04, 2025

InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews

May 04, 2025
pulisher
May 02, 2025

Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World

May 02, 2025

Finanzdaten der Inflarx N V-Aktie (IFRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):